Drug Profile

Dapagliflozin/Pioglitazone - Boryung Pharmaceutical

Alternative Names: BR-3003

Latest Information Update: 25 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boryung Pharmaceutical
Class Antihyperglycaemics; Benzhydryl compounds; Chlorobenzenes; Glucosides; Heart failure therapies; Obesity therapies; Pyrans; Small molecules; Thiazolidinediones; Urologics
Mechanism of Action Sodium-glucose transporter 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

20 Oct 2023 Dapagliflozin/Pioglitazone is still in phase III trials for Type 2 Diabetes mellitus in South Korea (Boryung Pharmaceutical pipeline, October 2023)
03 Jul 2022 Boryung Pharmaceutical completes a phase I trial for Type 2 diabetes mellitus in the South Korea (NCT05411965)
11 Feb 2021 BR 3003 is available for licensing as of 11 Feb 2021. http://www.boryung.co.kr/eng/rnd/pipeline.do

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com